Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose optimization and expansion study of SAR445877 in advanced gastric cancer or gastroesophageal junction adenocarcinoma
CTR20261921Phase 2Active
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SAR445877 in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Sanofi. Started Jun 2026; status: active.
02
Drugs
SAR445877
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20261921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261921.